These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 410415)

  • 21. Effect of low temperature on growth, viability, and synthesis of mycolic acids of Mycobacterium tuberculosis strain H37Ra.
    Takayama K; Armstrong EL; Davidson LA; Kunugi KA; Kilburn JO
    Am Rev Respir Dis; 1978 Jul; 118(1):113-7. PubMed ID: 98081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A model of isoniazid treatment of tuberculosis.
    Lemmer Y; Grobler A; Moody C; Viljoen H
    J Theor Biol; 2014 Dec; 363():367-73. PubMed ID: 25093828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin B 12 synthesis by Mycobacteria. II. Isoniazid resistance & vitamin B 12 activity of Mycobacterium tuberculosis H37Rv.
    Aithal HN; Sirsi M
    Indian J Biochem; 1964 Sep; 1(3):166-7. PubMed ID: 4243420
    [No Abstract]   [Full Text] [Related]  

  • 24. The mechanism of isoniazid killing: clarity through the scope of genetics.
    Vilchèze C; Jacobs WR
    Annu Rev Microbiol; 2007; 61():35-50. PubMed ID: 18035606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
    Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
    Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the proteome of isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis.
    Jiang X; Zhang W; Gao F; Huang Y; Lv C; Wang H
    Microb Drug Resist; 2006; 12(4):231-8. PubMed ID: 17227207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycolic acid index susceptibility method for Mycobacterium tuberculosis.
    Viader-Salvadó JM; Garza-González E; Valdez-Leal R; del Bosque-Moncayo MA; Tijerina-Menchaca R; Guerrero-Olazarán M
    J Clin Microbiol; 2001 Jul; 39(7):2642-5. PubMed ID: 11427584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and analysis of Mycobacterium tuberculosis mycolic acids.
    Vilchèze C; Jacobs WR
    Curr Protoc Microbiol; 2007 Jun; Chapter 10():Unit 10A.3. PubMed ID: 18770604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mycobacterial cell envelope-lipids.
    Jackson M
    Cold Spring Harb Perspect Med; 2014 Aug; 4(10):. PubMed ID: 25104772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: structure-activity relationships.
    Tandon R; Ponnan P; Aggarwal N; Pathak R; Baghel AS; Gupta G; Arya A; Nath M; Parmar VS; Raj HG; Prasad AK; Bose M
    J Antimicrob Chemother; 2011 Nov; 66(11):2543-55. PubMed ID: 21917615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis.
    Molle V; Gulten G; Vilchèze C; Veyron-Churlet R; Zanella-Cléon I; Sacchettini JC; Jacobs WR; Kremer L
    Mol Microbiol; 2010 Dec; 78(6):1591-605. PubMed ID: 21143326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
    Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro effect of ursolic acid on the inhibition of Mycobacterium tuberculosis and its cell wall mycolic acid.
    Jyoti MA; Zerin T; Kim TH; Hwang TS; Jang WS; Nam KW; Song HY
    Pulm Pharmacol Ther; 2015 Aug; 33():17-24. PubMed ID: 26021818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards understanding the functional diversity of cell wall mycolic acids of Mycobacterium tuberculosis.
    Verschoor JA; Baird MS; Grooten J
    Prog Lipid Res; 2012 Oct; 51(4):325-39. PubMed ID: 22659327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-to-function relationship of mycobacterial cell envelope components.
    Takayama K; Datta AK
    Res Microbiol; 1991 May; 142(4):443-8. PubMed ID: 1871431
    [No Abstract]   [Full Text] [Related]  

  • 36. [The mycolic acids analysis with HPLC technique in drug susceptibility testing of Mycobacterium tuberculosis strains].
    Walkiewicz R; Grubek-Jaworska H; Chazan R
    Pneumonol Alergol Pol; 2006; 74(1):89-94. PubMed ID: 17175985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The lipids of Mycobacterium tuberculosis BCG: fractionation, composition, turnover and the effects of isoniazid.
    Brennan PJ; Rooney SA; Winder FG
    Ir J Med Sci; 1970 Aug; 3(8):371-90. PubMed ID: 4990357
    [No Abstract]   [Full Text] [Related]  

  • 38. Mycolic acids from Mycobacterium tuberculosis: purification by countercurrent distribution and T-cell stimulation.
    Goodrum MA; Siko DG; Niehues T; Eichelbauer D; Verschoor JA
    Microbios; 2001; 106(413):55-67. PubMed ID: 11491525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the action of isoniazid.
    Youatt J
    Am Rev Respir Dis; 1969 May; 99(5):729-49. PubMed ID: 4306211
    [No Abstract]   [Full Text] [Related]  

  • 40. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target.
    Bhakta S; Besra GS; Upton AM; Parish T; Sholto-Douglas-Vernon C; Gibson KJ; Knutton S; Gordon S; DaSilva RP; Anderton MC; Sim E
    J Exp Med; 2004 May; 199(9):1191-9. PubMed ID: 15117974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.